Evidence mapPaperPMID 36148775Full record

ReviewClinical science (London, England : 1979)2022

Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways.

Olufunto O Badmus, Sarah A Hillhouse, Christopher D Anderson, Terry D Hinds, David E Stec

Open access · hybridAbstract readReview
In one paragraph

Review in Clinical science (London, England : 1979), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 212 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
212citing papers in PubMed, 1 pooled it
45.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

212 citing papers in PubMed, 1 synthesis or guideline pooled it, 324 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Fetuin-b Mediates Lipid Overload-Induced Hepatic Lipid Accumulation in Large Yellow Croaker (Larimichthys crocea).FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

152 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Olufunto O BadmusDepartment of Physiology and Biophysics, Cardiorenal, and Metabolic Diseases Research Center, University of Mississippi Medical Center, Jackson, MS 39216, U.S.A.
Sarah A HillhouseDepartment of Physiology and Biophysics, Cardiorenal, and Metabolic Diseases Research Center, University of Mississippi Medical Center, Jackson, MS 39216, U.S.A.
Christopher D AndersonDepartment of Surgery, University of Mississippi Medical Center, Jackson, MS 39216, U.S.A.
Terry D HindsDepartment of Pharmacology and Nutritional Sciences, Barnstable Brown Diabetes Center, Markey Cancer Center, University of Kentucky, Lexington, KY 40508, U.S.A.
David E StecDepartment of Physiology and Biophysics, Cardiorenal, and Metabolic Diseases Research Center, University of Mississippi Medical Center, Jackson, MS 39216, U.S.A.ORCID 0000-0001-8359-4008
University of Mississippi Medical Center · USMarkey Cancer Center · US

Funding

Integrative Role of Bilirubin on ObesityR01DK121748 · NIDDK · UNIVERSITY OF MISSISSIPPI MED CTR · PI DAVID E STEC · 2022 to 2023
$994k
NIDDK NIH HHS R01 DK121748NIDDK NIH HHS R01 DK121797NIGMS NIH HHS P20 GM104357
6 · The paper itself

Abstract

The metabolic-associated fatty liver disease (MAFLD) is a condition of fat accumulation in the liver in combination with metabolic dysfunction in the form of overweight or obesity and insulin resistance. It is also associated with an increased cardiovascular disease risk, including hypertension and atherosclerosis. Hepatic lipid metabolism is regulated by a combination of the uptake and export of fatty acids, de novo lipogenesis, and fat utilization by β-oxidation. When the balance between these pathways is altered, hepatic lipid accumulation commences, and long-term activation of inflammatory and fibrotic pathways can progress to worsen the liver disease. This review discusses the details of the molecular mechanisms regulating hepatic lipids and the emerging therapies targeting these pathways as potential future treatments for MAFLD.

Indexed as

Lipid MetabolismNon-alcoholic Fatty Liver DiseaseFatty AcidsHumansLipogenesisLiverTriglyceridesFatty AcidsTriglycerideshepatic steatosisintracellular signalingnon alcoholic fatty liver diseaseobesity

Identifiers

PMID36148775
PMCPMC9508552
OpenAlexW4296803763

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.